The Netherlands
Pan Cancer T is an emerging player in the biotech industry dedicated to revolutionizing cancer treatment. Founded in 2020, this spin-out from Erasmus MC, Rotterdam focuses on the discovery and development of T cell receptor (TCR) T cell therapies. The company leverages over two decades of expertise in adoptive T cell therapy to address the unmet needs of patients with solid tumors.
The innovative approach of Pan Cancer T involves the development of natural affinity TCR T cell therapies targeting unique intracellular markers present in a variety of solid tumors. This strategy aims to overcome hurdles posed by the tumor microenvironment, making these therapies more accessible and effective.
Pan Cancer T is poised to capture investors’ interest due to its transformative technology and strategic origin in a leading medical institution. As the company continues to progress, it represents a valuable opportunity for investors looking to be at the forefront of breakthrough cancer treatments.
